CA2041380A1 - Utilisation de la proteine c ou de la proteine c activee pour la preparation d'une composition pharmaceutique - Google Patents

Utilisation de la proteine c ou de la proteine c activee pour la preparation d'une composition pharmaceutique

Info

Publication number
CA2041380A1
CA2041380A1 CA2041380A CA2041380A CA2041380A1 CA 2041380 A1 CA2041380 A1 CA 2041380A1 CA 2041380 A CA2041380 A CA 2041380A CA 2041380 A CA2041380 A CA 2041380A CA 2041380 A1 CA2041380 A1 CA 2041380A1
Authority
CA
Canada
Prior art keywords
protein
pharmaceutical preparation
preparing
activated protein
activated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2041380A
Other languages
English (en)
Other versions
CA2041380C (fr
Inventor
Johann Eibl
Ludwig Pichler
Hans-Peter Schwarz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oesterreichisches Institut fuer Haemoderivate
Original Assignee
Immuno AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno AG filed Critical Immuno AG
Publication of CA2041380A1 publication Critical patent/CA2041380A1/fr
Application granted granted Critical
Publication of CA2041380C publication Critical patent/CA2041380C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002041380A 1990-08-16 1991-04-26 Utilisation de la proteine c ou de la proteine c activee pour la preparation d'une composition pharmaceutique Expired - Fee Related CA2041380C (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ATA1697/90 1990-08-16
AT0169790A AT402260B (de) 1990-08-16 1990-08-16 Protein c-hältige pharmazeutische präparation
EP91890012.7 1991-01-28
EP91890012A EP0471660B1 (fr) 1990-08-16 1991-01-28 Proteine C pour le traitement de la douleur

Publications (2)

Publication Number Publication Date
CA2041380A1 true CA2041380A1 (fr) 1992-02-17
CA2041380C CA2041380C (fr) 1997-10-07

Family

ID=3519039

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002041380A Expired - Fee Related CA2041380C (fr) 1990-08-16 1991-04-26 Utilisation de la proteine c ou de la proteine c activee pour la preparation d'une composition pharmaceutique

Country Status (12)

Country Link
EP (3) EP0533209B1 (fr)
JP (1) JP2530770B2 (fr)
AT (6) AT402260B (fr)
CA (1) CA2041380C (fr)
CZ (1) CZ280004B6 (fr)
DE (3) DE59108638D1 (fr)
DK (3) DK0533209T3 (fr)
ES (3) ES2103861T3 (fr)
HR (1) HRP921237A2 (fr)
HU (1) HUT60147A (fr)
RU (1) RU2066550C1 (fr)
YU (1) YU77591A (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571786A (en) * 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
AT397615B (de) * 1991-05-14 1994-05-25 Immuno Ag Arzneimittel enthaltend protein c
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
EP0733371B1 (fr) * 1995-03-21 2002-06-19 Baxter Aktiengesellschaft Agent pour l'application sous-coutanée de la protéine C
DE19608218A1 (de) * 1995-03-21 1996-09-26 Immuno Ag Mittel zur subkutanen Verabreichung von Protein C
WO2006072137A1 (fr) * 2005-01-07 2006-07-13 Northern Sydney And Central Coast Area Health Service Traitement des états pathologiques auto-immuns et inflammatoires
CA2877745C (fr) * 2012-07-04 2021-11-30 The University Of Sydney Traitement de troubles cutanes inflammatoires
ES2890675T3 (es) 2014-04-16 2022-01-21 Zz Biotech Llc APC para uso en el tratamiento de cicatrices cutáneas anormales

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock

Also Published As

Publication number Publication date
JPH04230633A (ja) 1992-08-19
DK0471660T3 (da) 1995-12-18
HUT60147A (en) 1992-08-28
EP0471660A2 (fr) 1992-02-19
ATE126699T1 (de) 1995-09-15
EP0471660B1 (fr) 1995-08-23
RU2066550C1 (ru) 1996-09-20
DE59108697D1 (de) 1997-06-05
ATA20492A (de) 1997-10-15
DK0533209T3 (da) 1997-09-22
AT403439B (de) 1998-02-25
ATA169790A (de) 1996-08-15
EP0533209B1 (fr) 1997-03-26
ES2080289T3 (es) 1996-02-01
ATA20392A (de) 1997-07-15
CA2041380C (fr) 1997-10-07
ATE150649T1 (de) 1997-04-15
AT402260B (de) 1997-03-25
JP2530770B2 (ja) 1996-09-04
DE59106292D1 (de) 1995-09-28
HRP921237A2 (en) 1995-10-31
ATE152354T1 (de) 1997-05-15
DE59108638D1 (de) 1997-04-30
EP0533209A1 (fr) 1993-03-24
ES2102435T3 (es) 1997-08-01
ES2103861T3 (es) 1997-10-01
CS121391A3 (en) 1992-02-19
EP0533210B1 (fr) 1997-05-02
EP0471660A3 (en) 1992-04-15
CZ280004B6 (cs) 1995-09-13
DK0533210T3 (da) 1997-11-03
EP0533210A1 (fr) 1993-03-24
AT403763B (de) 1998-05-25
YU77591A (sh) 1995-10-24
HU911348D0 (en) 1991-10-28

Similar Documents

Publication Publication Date Title
AU4869690A (en) Pyrazolopyridine compound and processes for preparation thereof
MA22668A1 (fr) Procede de preparation d'oxamides .
CA2145826A1 (fr) Derives de lipopeptide; methode de preparation et utilisation
CA2100212A1 (fr) Utilisation d'inhibiteurs du complement dans la preparation d'un produit pharmaceutique pour la prophylaxie et le traitement des affections inflammatoires de l'intestin et de la peau ainsi que du purpura
FR2605329B1 (fr) Procede de preparation de derives de metal du groupe 2 d'alkylphenols sulfures rendus surbasiques.
CA2079342A1 (fr) Composes pharmaceutiques multifonctionnels, leur methode de fabrication et leurs utilisations
CA2067381A1 (fr) Traitement des infections a vih et composes utiles a cet egard
AU7370491A (en) 2,8-dioxabicyclo(3,2,1)octane derivatives,their production from cultures of MF 5447 and MF 5466 and their use as anti hyper cholesterolemics
ES2010729A6 (es) Un procedimiento para prerparar un des-acil- antibiotico a 40926.
CA2041380A1 (fr) Utilisation de la proteine c ou de la proteine c activee pour la preparation d'une composition pharmaceutique
CA2097044A1 (fr) Acides a groupement cyclopentane- et pentene-.beta.-amino
DK0804228T3 (da) Lægemiddel indeholdende aktiveringspeptidet for protein C
CA2006087A1 (fr) Polypeptides isoles a partir du venin d'une araignee : hololena curta
AU7584891A (en) Treatment of osmotic disturbance with organic osmolytes
CA2018791A1 (fr) Compose capillaire
CA2067374A1 (fr) Promoteur de l'osteogenese
CA2179634A1 (fr) Analgesiques a base de 4-arylisoindole
CA2034926A1 (fr) Methode et compositions pour le traitement des intoxications
IE810808L (en) Isophthalic acid picolylamide monohydrate
CA2135310A1 (fr) 4'-methoxyacetophenones halogenees, microbicides et agents de preservation
FR2592892B1 (fr) Procede de preparation d'une poudre stable de micro-organismes et inoculum bacterien.
CA2014884A1 (fr) 5,11-dihydro-6h-pyrido[2,3-b] [1,4] benzodiazepin-6-ones et-thiones et leur utilisation dans la prevention ou le traitement du sida
EP0248361A3 (en) Pharmaceutical preparation for the treatment of bacterial infections
HK87195A (en) Process for the preparation of sulfated alkanol or alkylphenolox-ethylates with low content of 1,4 dioxane
AU1197388A (en) Treatment of rheumatoid arthritis with 3, 5-dichloromethotrexate

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed